Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
IMPLANT SCIENCES CORP (IMSC)
|
Add to portfolio |
|
|
|
| Price: |
$0.73
| | Metrics |
| OS: |
79.9
|
M
| |
|
|
| Market cap: |
$58.3
|
M
| |
|
|
|
Net cash:
|
$20.3
|
M
| |
$0.25
|
per share
|
|
EV:
|
$38
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jun-30-16 | Jun-30-15 | Jun-30-14 | Jun-30-13 | Jun-30-12 | Jun-30-11 | Jun-30-10 | Jun-30-09 |
| Revenues | 53.1 | 13.0 | 8.6 | 12.0 | 3.4 | 6.7 | 3.5 | 8.7 |
| Revenue growth | 308.4% | 51.9% | -28.8% | 252.8% | -48.8% | 91.5% | -60.2% | 69.6% |
| Cost of goods sold | 33.7 | 8.5 | 156.5 | 133.6 | 2.4 | 4.0 | 2.2 | 4.7 |
| Gross profit | 19.3 | 4.5 | -147.9 | -121.6 | 1.0 | 2.6 | 1.2 | 4.1 |
| Gross margin | 36.5% | 34.8% | -1730.0% | -1011.7% | 29.3% | 39.7% | 35.8% | 46.7% |
| Selling, general and administrative | 15.8 | 12.2 | 11.4 | 20.6 | 8.6 | 5.7 | 4.4 | 7.6 |
| Research and development | 4.1 | 5.0 | 4.8 | 4.8 | 3.2 | 2.7 | 2.4 | 3.3 |
| EBIT | 9.7 | -3.8 | -7.2 | -16.6 | -6.9 | -5.8 | -5.6 | -6.8 |
| EBIT margin | 18.2% | -29.6% | -84.6% | -137.8% | -201.9% | -87.6% | -160.5% | -77.8% |
| Pre-tax income | -0.5 | -12.7 | -14.1 | -22.0 | -10.8 | -15.6 | -15.4 | -13.6 |
| Income taxes | 10.2 | 8.8 | 6.9 | 5.4 | 3.9 | 0.0 | 0.1 | -0.8 |
| Tax rate | | | | | | 0.0% | | 6.0% |
| Earnings from continuing ops | -0.5 | -12.7 | -14.1 | -22.0 | -10.8 | -15.6 | -15.7 | -13.8 |
| Earnings from discontinued ops | | | | | | | -0.1 | 0.8 |
| Net income | -10.7 | -21.5 | -21.0 | -27.4 | -14.6 | -15.6 | -15.9 | -13.0 |
| Net margin | -20.1% | -165.8% | -245.7% | -227.6% | -429.7% | -233.8% | -456.3% | -148.3% |
| |
| Diluted EPS | ($0.01) | ($0.18) | ($0.23) | ($0.45) | ($0.32) | ($0.56) | ($0.81) | ($0.97) |
| Shares outstanding (diluted) | 78.2 | 70.8 | 60.8 | 49.1 | 34.0 | 27.7 | 19.5 | 14.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|